The EPS miss and accelerating cash burn are negative signals for a pre-revenue biotech with no near-term catalyst until summer 2026 enrollment completion. Monitor cash runway closely — the $14.2M cash (plus $10M offering) likely funds operations only into late 2026, requiring additional financing before Phase 3 data readout in early 2027. The 85% enrollment milestone is positive but insufficient to offset the financial deterioration.
Price Chart
Executive Summary
Annovis Bio reported Q1 2026 EPS of -$0.63, significantly below the -$0.35 consensus estimate, with R&D expenses tripling to $16.7M as the Phase 3 AD trial enrollment reached 85%. Cash burn accelerated to $17.6M net loss for the quarter, leaving $14.2M cash on hand (plus $10M from an April offering), funding operations into late 2026 but raising dilution risk ahead of pivotal data readouts in early 2027.
Key Financial Metrics
Key Facts
- Q1 2026 EPS -$0.63 vs consensus -$0.35 (80% miss); net loss widened to $17.6M from $5.5M YoY
- Cash and equivalents $14.2M at March 31, 2026, down from $19.5M at year-end 2025; excludes $10M April offering
- Phase 3 AD trial 85% enrolled; full enrollment expected summer 2026, top-line symptomatic data early 2027
- R&D expenses $16.7M vs $5.0M YoY, driven by Phase 3 trial costs; G&A flat at $1.3M
- Shares outstanding 28.5M at March 31, up from 27.2M at year-end 2025, reflecting ongoing dilution
Financial Impact
EPS miss of -$0.28 vs consensus; net loss increased $12.1M YoY; cash burn rate ~$5.9M/month
Risk Factors
- Cash runway insufficient to reach Phase 3 data readout without dilutive financing
- EPS miss and widening losses may pressure the stock given limited analyst coverage (1 analyst)
- Regulatory and clinical execution risk for buntanetap NDA submission in early 2027
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295755 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 10, 2026 12w ago | 8-K | $1.86 $1.88 | ▲ +1.08% | ▼ −1.35% | $1.18 (−36.56%) |
May 20, 2026 19w ago | 424B5 | $2.15 $1.73 | ▲ +19.53% | ▲ +19.87% | $1.18 (+45.12%) |
May 19, 2026 19w ago | 424B5 | $2.04 $1.75 | ▲ +14.22% | ▲ +14.96% | $1.18 (+42.16%) |
May 15, 2026 20w ago | 8-K | $2.05 $1.79 | ▼ −12.68% | ▼ −14.26% | $1.18 (−42.44%) |
May 15, 2026 20w ago | Press Release | $2.06 $1.78 | ▲ +13.59% | ▲ +15.71% | $1.18 (+42.72%) |
Apr 10, 2026 25w ago | Press Release | $1.59 $2.26 | ▲ +42.14% | ▲ +33.61% | $1.18 (−25.79%) |
Mar 19, 2026 28w ago | Press Release | $2.67 $1.87 | ▼ −29.96% | ▼ −37.58% | $1.18 (−55.81%) |
Mar 16, 2026 28w ago | Press Release | $2.83 $1.73 | ▼ −38.87% | ▼ −42.65% | $1.18 (−58.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access